



Repositorio Institucional de la Universidad Autónoma de Madrid

<https://repositorio.uam.es>

Esta es la **versión de autor** del artículo publicado en:
This is an **author produced version** of a paper published in:

Glycobiology 25.2 (2015): 197-210

DOI: <http://dx.doi.org/10.1093/glycob/cwu103>

Copyright: © 2014 The Author

El acceso a la versión del editor puede requerir la suscripción del recurso
Access to the published version may require subscription

**INTERACTIONS OF HUMAN GALECTINS WITH *Trypanosoma cruzi*.
Binding profile correlates with genetic clustering of lineages**

Miguel A Pineda^{2,3}, L. Corvo ², M. Soto ², M. Fresno Escudero ² and P. Bonay ^{1,2}.

²Centro de Biología Molecular “Severo Ochoa”- Universidad Autónoma de Madrid.
Campus de Cantoblanco. Madrid 28049. Spain.

³ 1Institute of Infection, Immunity and Inflammation, Glasgow Biomedical Research Centre, University of Glasgow, 120 University Place, Glasgow G12 8TA, United Kingdom

Keywords: Discrete Typing Units / Galectin / Host cell adhesion / *Trypanosoma cruzi*.

¹To whom correspondence should be addressed:

Pedro Bonay

Centro de Biología Molecular “Severo Ochoa”

Universidad Autónoma de Madrid.

Nicolás Cabrera 1

Cantoblanco. Madrid 28049.

Spain.

Pone: +34-911964509

Fax: +34-914974799

E-mail: pbonay@cbm.uam.es

Abstract.

We report here the specific interaction between several members of the human galectin family with the three developmental stages of several genetic lineages of the protozoan parasite *Trypanosoma cruzi*. We provide data of specific and differential binding of human galectins-1, 3, 4, 7 and 8 to 14 strains of *T. cruzi* that belong to the six genetic lineages representing the genetic diversity of the parasite. It is shown that galectins preferentially bind forms present in the host, trypomastigotes and amastigotes, compared to the non-infective epimastigote present on the intestinal tract of the vector, reflecting the changes on glycosylation that occur during the metacyclogenesis and amastigogenesis process. Also, it is evidenced that galectin binding to the parasites promotes binding to the host cells and higher infection rates. In addition evidence is provided indicating that the intracellular amastigotes may take over the cytosolic pool of some galectins when released to the extracellular medium. Finally, by applying unweighted pair group method analysis to the galectin binding profile to either cell-derived trypomastigotes or amastigotes we show that the differential binding profile by the host galectins to the six lineages resembles the clustering based in genetic data. Therefore, the differential binding profile for the six lineages could have implications in the immunopathology of Chagas' disease, affecting the complex network of immune responses on which galectins mediate, thus providing linkage clues to the notion that different lineages may be related to different clinical forms of the disease.

Introduction.

Trypanosoma cruzi is the causative agent of Chagas' disease or American trypanosomiasis, a chronic and debilitating multisystemic disorder that affects more than 8-10 million people in Latin America (World, O.H. 2010). The disease exhibits a diverse spectrum of clinical manifestations, starting with a short acute phase with variable parasitemia characterized by strong immunosuppression, followed by an indeterminate phase when no clinical symptoms are observed (Biolo, A., Ribeiro, A.L., et al. 2010, Coura, J.R. and Borges-Pereira, J. 2010, Rassi, A., Jr., Rassi, A., et al. 2010). Nevertheless, a significant proportion of infected individuals develops a subsequent symptomatic chronic phase categorized in at least three clinical forms, in which the digestive (megacolon) and heart disease (chagasic cardiopathy) are the most common, but also involving skin (Hemmige, V., Tanowitz, H., et al. 2012) and nervous system disorders (Chuenkova, M.V. and Pereiraperrin, M. 2011, Py, M.O. 2011). Interestingly, some geographical distribution is associated to the disease clinical manifestations, perhaps reflecting the genetic variability of *T. cruzi*, and ultimately it may be also related to how the host immune response is elicited, including the pathogen sensing by the innate immune system, the perpetuation of inflammatory and autoimmune responses, as well as the ability to control parasitemia and chronic parasite persistence. However, the host factors responsible of triggering immune mechanisms during disease initiation and progression still remain undetermined. *T. cruzi* has a complex life cycle with three different life forms (Brener, Z. 1973, de-Souza, W. 1984). The parasite is taken from infected mammals in the blood meal of the insect as blood trypomastigotes which undergo transformation to epimastigotes that migrate to the hindgut. After 3-4 weeks, they transform into infective non-dividing metacyclic trypomastigotes that are released in the feces onto skin or mucosa of the vertebrate host, where they are able to invade a wide variety of host mammalian cells, (de-Souza,

W. 1984, Pereira, M.E. and Krettli, A.U. 1990). Once inside the cells, they transform into intracellular amastigotes, which then multiply till rupture of host cells, when they differentiate into bloodstream trypomastigotes that disseminate via lymphatics and bloodstream, before going through another intracellular cycle or are taken up by the insect again closing the life cycle. In order to adapt and survive into these different environments, the parasite presents very different composition of the plasma membrane and interestingly, the most dramatic changes are observed in the glycosylation profile of each biological form (Buscaglia, C.A., Campo, V.A., et al. 2006, de Lederkremer, R.M. and Agusti, R. 2009).

Trypanosoma cruzi is a highly genetically diverse organism and it has been clustered into six Discrete Typing Units (DTUs) on genetic basis, that exhibit some degree of differential geographical distribution, virulence, tissue tropism and susceptibility/resistance to drugs (Aquilino, C., Gonzalez Rubio, M.L., et al. 2012, Macedo, A.M., Machado, C.R., et al. 2004). It has been suggested that the genetic polymorphism of the parasite population could be related to the diverse clinical manifestations of the disease (Macedo, A.M., Machado, C.R., et al. 2004). However, little is known about the host molecules involved on the differential parasite recognition and therefore, a systematic study is urgently needed to understand the multiple clinical outcomes of Chagas disease. Importantly, most of the pathogen-associated molecular patterns (PAMPs) described so far in *T. cruzi* are glycosylated (such as GPI-linked, mucins and trans-sialidases) and are indeed essential to control activation of the innate immune system and initiation of the acquired host immune response in the vertebrate host (Alcaide, P., Lim, Y.C., et al. 2010, Almeida, I.C., Camargo, M.M., et al. 2000, Nogueira, N.F., Gonzalez, M.S., et al. 2007, Previato, J.O., Wait, R., et al. 2004, Procopio, D.O., Almeida, I.C., et al. 2002). Therefore, characterization of the interaction between parasite glycans and their host's putative Pattern Recognition Receptors (PRRs) is of outstanding relevance. Among the wide array of PRRs, galectins have

attracted attention over the last years due to the large number of immune functions ascribed to them (Vasta, G.R. 2012). Galectins are an evolutionarily conserved family (so far 12 genes in humans) of animal lectins with preserved structure and calcium-independent affinity for β -galactosides (Vasta, G.R. 2012), yet exhibiting different fine specificity and affinity. They are widely expressed on diverse cell types, from immune-privileged tissues to epithelial cells of intestinal tract. However, each one exhibits a restricted tissue distribution (Nio-Kobayashi, J., Takahashi-Iwanaga, H., et al. 2009), and show a pleiotropic range of effects mainly related to inflammatory processes including but not limited to apoptosis, cell adhesion and migration, regulation of cell growth and pathogen recognition. Collectively, the final interplay of the galectin signalling network will be the cumulative result of each individual member interacting with its cognate ligands. It has become increasingly clear that different regulatory immune circuits can be associated to multiple activation of immune pathways triggered by PRRs (Amit, I., Regev, A., et al. 2011, Boonstra, A., Rajsbaum, R., et al. 2006, Chevrier, N., Mertins, P., et al. 2011, Dam, T.K. and Brewer, C.F. 2010, Dam, T.K. and Brewer, F.C. 2010, Trinchieri, G. and Sher, A. 2007). Hence, having several members of the galectin family to differentially scrutinize and mediate pathogen recognition constitutes a powerful mechanism to fine tune the subsequent immune response.

To date, there have been some reports suggesting that galectins are intimately linked to some aspects of *T. cruzi* infection, such as changes in expression of galectins and/or its ligands upon *T. cruzi* infection (Silva-Monteiro, E., Reis Lorenzato, L., et al. 2007, Vray, B., Camby, I., et al. 2004, Zuniga, E., Gruppi, A., et al. 2001, Zuniga, E., Rabinovich, G.A., et al. 2001), including changes in subcellular location of gal-3 (Machado, F.C., Cruz, L., et al. 2014, Reignault, L.C., Barrias, E.S., et al. 2014). It has also been shown that gal 3 is able to promote trypomastigotes adhesion to extracellular matrix components (Kleshchenko, Y.Y., Moody, T.N., et al. 2004, Moody, T.N., Ochieng, J., et al. 2000). However, the relevance of galectins in *T. cruzi* infection is still

far from being resolved and there is no systematic study showing a direct interaction of specific galectins with neither different life forms of the parasite nor with individual *T. cruzi* lineages that often exhibit different pathology.

Here we report the binding profile of several members of the human galectin family towards the three life forms of the human pathogen *T. cruzi*. Galectins present a higher affinity to biological forms found in the vertebrate host, such as trypomastigotes and intracellular amastigotes, compared to the non-infective epimastigotes present in the insect vector. Secondly, consistent with the role of galectins in the initiation of the immune response, by using unweighted pair-group method analysis of galectin binding profile of epimastigotes and cell-derived trypomastigotes of the six different DTUs,¹⁴ *T. cruzi* strains analysed could be arranged in five clusters that closely resembled the grouping based solely on genomic data. And last, we demonstrate that intracellular amastigotes are able to take over or “sequester” the soluble pool of intracellular host galectins that may affect the subsequent binding to non-infected host cells and the recognition by the host immune system. The implications of galectin-mediated recognition of *T. cruzi* on the evolution of parasite lineages and their differential outcome in Chagas pathology is discussed.

Materials and methods.

Cells and Parasites.

Vero (Green monkey kidney epithelial cells, ATCC CCL-81), LLC-MK2 (Rhesus monkey, kidney epithelial cells, ATCC CCL-7), CaCo-2 (Human colorectal adenocarcinoma cells, ATCC HTB-37) and THP-1 (Human monocytes ATCC TIB-202) cells were grown in RPMI complete medium containing 5% FCS, 2 mM L-glutamine, penicillin (100U/ml) and streptomycin (100 µg/ml) (Gibco, Grand Island, NY) at 37 °C in an atmosphere containing 5% CO₂. The mouse cardiac cell line HL-1 (Claycomb, W.C., Lanson, N.A., Jr., et al. 1998) was obtained and grown according to Dr. Claycomb (Department of Biochemistry & Molecular Biology, School of Medicine, Louisiana State University).

All parasite strains listed in Table I were genotyped as described in (Zingales, B., Miles, M.A., et al. 2012) and DTU assigned according to the new consensus on nomenclature on genetic lineages of *T. cruzi* (Zingales, B., Andrade, S.G., et al. 2009). Epimastigotes life forms were continuously cultured in liver infusion tryptose medium supplemented with 5% fetal calf serum, and 0.01% hemin as described previously (Alcina, A. and Fresno, M. 1988). Cell derived trypomastigotes (CTT) were obtained from the supernatant of infected Vero cells at 4-6 days post-infection and isolated by differential centrifugation, and recovered from the supernatant after 2 hours incubation at 37°C, this procedure was repeated once to reduce the proportion of intermediate forms and amastigotes. The final population was never less than 95% highly motile trypomastigotes.

Amastigotes were obtained from 3-4 days infected Vero cells after lysis, either by Percoll discontinuous density gradient as described (Gamarro, F., Osuna, A., et al. 1985) or by anion-exchange chromatography (Marques, A., Nakayasu, E., et al. 2011). Microscopic examination indicated that 98% or 95% respectively, of the population was

homogeneous. No differences in the binding profile were detected. Given the highly consistent yield of the Percoll gradient method, it was the preferred method.

Galectins.

Expression plasmid pQE60 containing the human galectin-1 sequence was kindly provided by Dr. Elena Moiseva (Leicester Warwick Medical School, UK). The protein was purified as described previously (Andersen, H., Jensen, O.N., et al. 2003).

Expression plasmids for human galectin-3 and galectin-4 were provided by Dr. Hakon Leffler (Lund University, Sweden) (Patnaik, S.K., Potvin, B., et al. 2006). Expression plasmid pGEX containing the human galectin-7 sequence were provided by Dr. Thierry Magnaldo (Institut Gustave Roussy, France) (Magnaldo, T., Bernerd, F., et al. 1995).

Four expression plasmids pGEX4T2 containing the human galectin-8 sequence and the mutant galectin-8 R69H, galectin-8 R233H, and galectin-8 R69H/R233H sequences were provided by Dr. Nozomu Nishi (Kagawa University, Japan) (Nishi, N., Shoji, H., et al. 2003). All human recombinant galectins were expressed and purified from bacterial pellets as described in the original manuscripts and freed of LPS (Lipopolysaccharide) by passage on a polymixin-Sepharose™ column as described by the manufacturer.

Briefly, bacteria cultures were incubated with 1mM isopropyl-1-thiogalactopyranoside for 3h at 37 °C to induce recombinant protein production. Bacteria were pelleted, suspended in phosphate-buffered saline 4mM EDTA, 2 mM β -mercaptoethanol, 10mM lactose (PBS-MELac) together with a protease inhibitor cocktail. After sonicating, bacteria were centrifuged to obtain the soluble fraction. Recombinant galectins present in this fraction were purified by affinity chromatograph on α -lactose-agarose and eluted with lactose 0.1 M and dialysed against a buffer containing 0.1mM β -mercaptoethanol and 10 μ M lactose. Once purified, each galectin was kept at -20°C after freeze-drying solutions at concentrations above 10 μ Molar, in such way galectins were stable for a longer time avoiding proteolysis. Before each experiment, the integrity and purity of each galectin was assessed by SDS-PAGE and silver staining, and their sugar binding

capacity was periodically tested (Figure 2 shows a representative silver stained gel of purified recombinant human galectins as used on this manuscript). Alexa-488-conjugated galectins were prepared by labelling with Alexa Fluor 488 Microscale Protein Labelling Kit (Life Technologies) following manufacturer guidelines. Truncated galectin 3 was obtained as described before (Kopitz, J., von Reitzenstein, C., et al. 2001).

Adhesion and infection assays of *T. cruzi* to host cells

To study parasite-cell adhesion, THP-1 and LLC-MK2 were used. *T. cruzi* cell-derived trypomastigotes were labelled with the fluorescent dye CFSE according to manufacturer's instructions (carboxyfluorescein diacetate, succinimidyl ester, Life Technologies). THP-1 cells (10^6 cells/assay) were incubated with CFSE-labeled parasites in complete RPMI medium (cell:parasite ratio 1:3) for 15 min at 4°C to prevent parasite internalization with or without recombinant galectins.. Then, cells were fixed in 1% paraformaldehyde in PBS. Samples were analysed by Flow Cytometry using a FACScalibur flow cytometer (BD Biosciences). Fluorescence associated to mammalian cell gating was quantified as an indication of cell-attached parasites. To study adhesion of *T. cruzi* to LLC-MK2 cell line, cells were cultured in microtiter plate wells and cell derived trypomastigotes were added to each cell in a 1:10 cell:parasite ratio, in the presence or absence of recombinant galectins (0.2-2µM) at 4°C for 15 minutes. After PBS washing, the number of parasites attached to the cells was directly counted in not less than 10 representative fields.

Vero or LLC-MK2 cells growing on glass coverslips at 25% confluency in 24 well plates were used for infection assays. Cell-derived tripomastigotes were added at an infection index of 10 for 4 hours at 37°C, in the presence or absence of indicated galectins. The cells were washed three times to remove unattached parasites and kept at 37°C.

At indicated times, cells were washed twice with PBS, fixed with Bouin's fixative solution and stained in Giemsa solution. The number of infected cells and number of

intracellular amastigotes per cell were quantified counting at least 150 cells in three independent slides by two different observers.

Flow Cytometry assays.

Parasites were incubated with Alexa-488-labelled galectins (2 μ M) for 15 minutes at 4°C. Unbound galectins were removed by washing three times with PBS, and parasites were then fixed in 1% paraformaldehyde for 20 minutes at 4°C. Relative fluorescence intensity was measured on a FACScalibur flow cytometer (BD Biosciences) and data were analysed using FlowJo analysis software (Tree Star).

Identification of *T. cruzi* galectin ligands.

To prepare galectin immobilized columns, 5-10 mg of gal-3 and 4 (purified as previously described) were covalently coupled to HiTrap NHS-activated columns according to manufacturer's instructions (Amersham Biosciences), including 5mM lactose in the coupling buffer. Gal-7-GST and gal-8-GST were coupled to glutation-Sephadex columns.

Membrane proteins of cell-derived trypomastigotes (Y strain) were obtained by labeling live parasites with Sulfo-NHS-SS-Biotin, lysed in buffer B (0.2 M NaCl, 20 mM Tris-HCl, 0.1% CHAPS and protease inhibitors cocktail). The solubilized cell surface biotinylated proteins were purified by chromatography on a Neutravidin column (Pierce) and eluted with DTT 50mM. The eluted fraction was applied to columns containing the immobilized galectins. Columns were extensively washed with buffer B and buffer B plus 0.5M NaCl, and then specifically eluted with buffer B plus 100 mM lactose. The eluted material was resolved by SDS-PAGE, transferred to nitrocellulose filters and probed with biotinylated galectins.

Identical nitrocellulose membranes lanes were cutted into 10 slices, reduced with dithiothreitol, alkylated with iodoacetamide and digested overnight with trypsin in a 1:40 ratio. Peptides released were acidified with trifluoroacetic acid (TFA, final 0.1%), dried and redissolved in 5 μ l TFA% and acetonitrile 33%. DHB (2,5-dihydroxybenzoic acid) 0.5 μ l was used as matrix and mixed with 0.5 μ l of peptide sample on a Anchor-chip

(Bruker) and air dried. The spectra obtained were used for MASCOT in-house identification searches against the TryTrypDB *T. cruzi* protein database (Tcruzi_AnnotatedProteins-v7.0, <http://TryTrypDB.org>). The *T. cruzi* surface mucin AgC10 was identified among the galectin ligands by using a specific monoclonal antibody previously described by our laboratory (Alcaide, P. and Fresno, M. 2004a, Alcaide, P. and Fresno, M. 2004b).

Confocal immunofluorescence microscopy.

To study the subcellular location of endogenous galectins in infected cells, Vero cells were grown on cover slips to 25-30% confluence and then infected at an infection index (parasite:cell) of 10 with trypomastigotes, strain Y (DTU II), during 4h at 37 °C, after which free parasites were removed by washing three times with medium before incubate them at 37 °C in an atmosphere containing 5% CO₂. After 3 days, the cells were fixed with 1% paraformaldehyde-0.5% glutaraldehyde in buffer sodium cacodylate 50 mM pH 7.1, 70mM NaCl, 0.1% saponin; washed three times with PBS-0.2% BSA, incubated with anti-galectin antibody and subsequently with Alexa-488-conjugated secondary antibody before images were acquired using Confocal LSM510 META microscope (Zeiss).

Unweighted Pair-Group Method with Arithmetic Mean (UPGMA) Analysis

The clustering was done using Pearson coefficient comparing the Medium Fluorescence intensity (MFI) of each DTU when tested against fluorescent conjugates of recombinant galectin 1, 3, 4, 7 and 8 by using DendroUPGMA (Garcia-Vallve, S., Palau, J., et al. 1999).

Results.

Galectins bind to *Trypanosoma cruzi*.

First, we screened the binding of highly purified recombinant human galectins conjugated to Alexa-488 by flow cytometry to live epimastigotes, amastigotes and cell-derived trypomastigotes. The purity of the recombinant galectins employed in the study was assessed by silver-stained SDS-PAGE gel (Figure 1). Individual life forms of *T. cruzi* were analyzed separately. Fig.2A shows a representative flow cytometry histogram obtained for the Y strain (DTU TcII) in which a differential binding profile is observed. There was a higher affinity (in terms of higher MFI) to the forms present in the host i.e.- cell-derived trypomastigotes and amastigotes, than to the non-infective *in vitro* cultured epimastigotes to which only gal-7 showed a binding clearly distinctive from negative controls. Gal-7 and gal-8 showed the highest affinity when trypomastigotes were tested, whereas gal-1 and gal-4 were shown to bind amastigotes (Fig. 2B) in a clear indication of different glycan exposition on the different life forms, evidencing substantial differences in the specificity for each galectin. We did not find any quantitative difference between trypomastigotes obtained by metacyclogenesis or cell-derived trypomastigotes (not shown), suggesting that the change in the surface exposed glycans is inherent to the life form and not to the differentiation strategy used to generate them. The binding to cell-derived trypomastigotes was saturable, reaching a plateau at galectin concentrations close to 20 μ M (Fig. 2C) similar feature was found for amastigotes and epimastigotes (not shown).

As galectins are soluble proteins located in the cytosol, it is reasonable to propose that the intracellular pool might bind to amastigotes exposing galactosides on their surface. In order to test this, purified extracellular amastigotes from disrupted-cell supernatants were galactose washed in order to remove any host galectin bound. Under those conditions, the binding of galectins to parasites was significantly increased for gal-1, 3 and 7 ($p < 0.01$, Figure 3A). This is a clear indication that amastigotes are recruiting intracellular galectin (or any other galactoside-binding protein) from the infected host

cells cytosolic pool. No significant difference was observed regarding gal-4 and 8. In contrast, when cell-derived trypomastigotes were subjected to the galactose wash; no increase in the MFI was found when compared to control non-washed trypomastigotes (Fig 3A), suggesting either they are not recruiting intracellular galectin or, the bound proteins are released/processed shortly after being exposed to the extracellular milieu. Another alternative is that trans-sialidase action makes any galactose exposed cryptic for the galectins.

The protein content obtained after galactose washing of isolated intracellular amastigotes was subjected to SDS separation and western-blot to detect host galectins by using specific antibodies or streptavidin-HRP to detect biotinylated-galectin 7 (Figure 3B). As expected, when sucrose or mannose was used instead of galactose, galectins were not released from amastigotes, and it did not affect galectin binding observed by FACs (not shown).

An alternative explanation to the “coating” with endogenous galectins as responsible for the diminished binding of exogenous galectins would be that the recently released amastigotes do not expose the galectin ligands and are unmasked or exposed immediately after being released in the media.

In order to test this hypothesis, we set up *in vitro* infections of LLC-MK2 or Vero cells and after 4/5 days the cells were processed for immunofluorescence to examine the pattern of endogenous galectin distribution. Interestingly, non-infected cells expressed an uniform cytosolic staining pattern for gal-1, and 3 (Fig.4 D-E, arrow head), in clear contrast to infected cells where galectin expression was accumulated on the cell surface of intracellular amastigotes (Fig. 4A-B arrows), confirming that intracellular amastigotes are coated by host endogenous galectins. The possibility of a cross-reacting endogenous parasite protein homologous to host galectin was ruled out by flow cytometry (as is shown in the controls in Fig.3A) and reports in the literature showing no specific cross-reactivity of anti-gal antibodies against *T. cruzi* antigens (Giordanengo, L., Gea, S., et al. 2001).

Galectin binding to parasites is Carbohydrate Recognition Domain (CRD)

dependent.

Our data showed that the binding of galectins to *T. cruzi* was inhibited by lactose, but not sucrose, suggesting that the lactose-binding domain is involved in the parasite-protein interaction. To confirm that the binding of the human galectins to the parasites was CRD-mediated, we next carried out the binding assays in the presence and absence of specific inhibitory ligands of galectins. Galectin binding was completely inhibited by lactose at 50 mM (Fig. 5A) or thiodigalactoside at 10 mM, indicating that the CRD was involved in the recognition to the sites exposed on the surface of the parasites. However, we failed to inhibit galectin binding when β -galactosidase-treated parasites were used, perhaps as a result of an incomplete access of β -galactosidase to the ligands due to steric hindrance from the dense mucin layers or/and to high protein turnover rate found in *T. cruzi*.

Unambiguous evidence supporting the implication of the CRD for the tandem-repeat galectin-8, was obtained by using the recombinant human protein carrying punctual mutations (gal-8R69, gal-8R233 and gal-8R69R233, resulting in a non-functional N-terminal, C-terminal and both N- and C-terminal CRDs respectively), that abolished the binding to their natural ligands (Nishi, N., Itoh, A., et al. 2006). Gal-8R69, and gal-8R233 presented reduced binding to cell-derived trypomastigotes and an the null double mutant showed an absolute lack of binding, confirming that the CRD of gal-8 is directly involved in the binding to parasite ligands.

Gal-3 is the only one member of the chimera-type galectin group, constituted by a CRD at the C-terminus and a collagen-like domain at the N-terminus that could bind *T. cruzi* in a CRD-independent manner. In order to determine which domain of gal-3 is responsible for the interaction with *T. cruzi*, we studied the binding properties of a truncated gal-3 constituted only by the C-terminus domain including the CRD after releasing the collagenous domain by collagenase treatment (Kopitz, J., von Reitzenstein, C., et al. 2001). As shown in Figure 5C, removal of the collagen-like N-

terminal domain does not affect the binding to trypomastigotes and amastigotes, indicating that the the recognition and binding of gal-3 to the parasite is also CRD-mediated. .

Galectin binding promotes adhesion to host cells.

We next tried to address the functional relevance of the galectin-trypomastigote interaction on parasite adhesion and/or infection to host cells. To evaluate this we next performed *in vitro* adhesion and infection assays using several cell lines as models.

Parasite adhesion to THP-1 cells in the presence of recombinant galectins was quantified by using a cell cytometry approach in which the gating of free CFSE-labeled live cell-derived trypomastigotes (strain Y) can be easily separated from unlabeled THP-1 cells according to their respective forward and size scatter values. Therefore, any increase in fluorescence in the cell's gate is proportional to the number of CFSE-labelled parasites that have been attached to those cells. Mixtures of parasites and cells in the presence or absence of galectins were submitted to analysis. We limited the analysis time to 15 minutes in order to look just for adhesion, and the temperature to below 16°C to keep parasites live but blocking endocytosis of galectins, limiting protease activity. A positive correlation between the affinity shown by individual galectins and their ability to promote parasite adhesion to host cells was observed (Fig. 6A). Thus, gal-3, gal-7 and gal-8, the galectins that showed a higher affinity towards parasite infective forms, were those that promoted parasite adhesion to THP-1 cells, whereas, gal-1 and gal-4, with lower affinity towards trypomastigotes (strain Y), did not increase parasite adhesion to THP-1 cells compared to control (no exogenous galectin). Similar results were obtained with other different strains tested (data not shown).

Like the galectin binding to isolated cells, the galectin-mediated adhesion of parasite to host cells was shown to be dependent on the CRD as it was abolished by specific haptens, such as lactose, or by mutation of both CRDs found in gal-8 (Fig. 6B).

As monomeric gal-1 and gal-7 exhibited concentration-dependent oligomerization affecting their valency, we decided to test the effect of such functional aggregation concentration dependent on the binding. Thus, two concentrations of gal-1 and gal-7 were tested; 0.2 μ M (mainly monomeric) and 2 μ M (mainly dimeric and/or higher oligomers). The data shown in Fig. 6C suggest that cell-binding promoting activity of this galectin relies on its multivalent properties acting as a molecular bridge between parasites and host cells.

Similar assays were carried out with several adherent cell lines to mimic the physiological environment found in vivo, where *T. cruzi* infects epithelial cells, showing a broadly similar pattern of galectin induced adhesion (Fig. 6D).

To further investigate the relevance of galectin-*T. cruzi* interaction, a new set of experiments was conducted to define whether the observed galectin-mediated adhesion to host cells translates into higher infection rates. Data shown in Fig. 7 supports that idea, as in the presence of galectins, concomitant with an increased binding to the host cells, there is an increased infective ability evidenced by both the number of infected cells (Fig. 7A) and the number of amastigotes per cell (Fig. 7B).

Identification of surface mucins as galectin ligands on *T. cruzi*.

Once it was shown that galectins bind to *T. cruzi*, attempts to identify the galectin ligand on the parasite cell surface were carried out by using biotin-labeled recombinant galectins. It was detected a diverse array of protein bands ranging from 10 to 100 KDa, specific and variable for individual galectins. A discrete band around 80-70 KDa was common for all galectins tested, however the total number of proteins detected was qualitatively different for each galectin (Fig. 8A). Gal-4 seemed to be the more restricted ligand galectin, with just the band around 80-70KDa detected in the eluate, in contrast to gal-1 that showed the most complex pattern of ligands. Interestingly, gal-7 and gal-8 showed an almost identical pattern of ligands. To identify the parasite proteins contained in the samples, identical membranes were sliced and subjected to peptide mass fingerprinting. The identified proteins are shown in Table IV. By using

specific antibodies against parasite mucins, the presence of the mucin AgC10 among the human galectin-7 and galectin-8 ligands was demonstrated (Figure 8B).

Unweighted Pair-Group Median Arithmetic analysis.

As galectins are relevant factors in the outcome of immune responses, we decided to test whether a differential galectin binding could be associated to different DTUs described for *T. cruzi*, since DTUs are also associated to clinical manifestations. A similar binding pattern to different *T. cruzi* strains would indicate that inter-strain differences on exposed glycans are not significant and hence not being a discriminatory element, or by contrast, showing strain specific galectin binding (distinguishing specific traits like type of galactose containing glycans exposed on the cell surface). In a similar fashion as the referenced strain Y, intracellular amastigotes and cell-derived trypomastigotes from the strains tested (Table I) were the forms that showed the highest binding for all galectins tested. Furthermore, some differences were found when the Median Fluorescence Index (MFI) for each galectin binding profile was analysed (shown in Table II and III). Based on these differences, we decided to carry out an Unweighted Pair-Group Median Arithmetic (UPGMA) analysis of MFI values vs. DTUs to identify whether there was a common pattern for strains belonging to the same lineage. The resulting dendrogram shows that the 14 strains were grouped in six clearly discrete clusters when cell-derived trypomastigotes were analysed (Fig. 9A) and in five clusters when amastigotes were utilised (Fig. 9B) where the last cluster included strains from DTUs IV and V.

Discussion.

Specific interactions between galectins and glycoconjugates are considered to be critical determinants in pathogen recognition (Paz, I., Sachse, M., et al. 2010, Rabinovich, G.A. and Gruppi, A. 2005, Vasta, G.R. 2009). There is no direct evidence whatsoever regarding different galectins binding to the three life forms of this pathogen, and more important yet, there is no data on differential interaction of innate immune components (c-type lectins, galectins etc.) to different parasite genetic lineages. Under this premise, we decided to ascertain whether different human galectins are able to specifically recognize glycans exposed on the cell surface of the three life forms of the pathogenic parasite *Trypanosoma cruzi*.

It is known that the parasite surface glycoconjugates are different in every biological stage of the parasite (Bourguignon, S.C., de Souza, W., et al. 1998, Colli, W. and Alves, M.J. 1999, de Lederkremer, R.M. and Agusti, R. 2009, de_Lederkremer, R.M. and Colli, W. 1995, Ferguson, M.A. 1997). Our results show that the life forms present in the host (amastigotes and trypomastigotes), are recognized to a greater extent than the non-infective epimastigotes, reflecting the changes that take place in membrane composition, accessibility and exposure of glycans on the infective forms, probably related to the infective capacity.

The major glycoconjugates of *T. cruzi*, the mucins, are longer in the trypomastigotes and contain additional α -galactopyranosyl residues (Almeida, I.C., Gazzinelli, R., et al. 1999, Buscaglia, C.A., Campo, V.A., et al. 2006). Those changes are supposed to allow adaptation and survival in a new environment, where the parasite will encounter immune mechanisms controlled by immune regulators, such as galectins. Whether the parasite evolved to display galectin ligands in the infective forms, or the host developed galectins with greater affinity towards infective form glycans is difficult to predict over the common evolutive pressure of both parts. In that context is worth mentioning that mannose receptor and mannose binding proteins have been described to favour

binding of amastigotes to macrophages that had not been activated by IFN- γ (Kahn, S., Wleklinski, M., et al. 1995).

We observe that intracellular amastigotes are the parasite form that binds galectins with the highest affinity. In that sense, it results interesting that intracellular amastigotes are “coated” with the cytosolic soluble galectin pool from infected cells. It has been described an alternative infection cycle inside the host, where intracellular amastigotes released from lysate cells may initiate a new round of infection by attaching and then infecting neighbour cells. Besides altering the normal functions of cytosolic galectins (by altering the intracellular pool), that galectin coating of amastigotes could favour a fast entry into neighbour cells by promoting adhesion and facilitating invasion with galectins acting as bridge between cells and parasites. Another possibility for the “decoration” with galectins would be to induce a receptor rearrangement of the galectin lattice at the host cell surface modifying in that way the signalling pathways that allow the amastigote to survive in the extracellular milieu before obligate transformation to trypomastigotes or initiate a new invasion cycle or simply tagging the amastigotes with a danger signal that favours the engulfment by macrophages. Whether this “coating” or “recruiting” of intracellular galectins confers to the parasite any advantage is just a matter of speculation at the moment. Remarkably, recent findings showed a recruitment of structures expressing gal-3 to vacuoles containing *T. cruzi* amastigotes (Machado, F.C., Cruz, L., et al. 2014, Reignault, L.C., Barrias, E.S., et al. 2014), and some reports showed that gal-3 covers intracellular Mycobacterium-containing phagosomes promoting pathogen killing (Beatty, W.L., Rhoades, E.R., et al. 2002). An intriguing alternative is that sequestering cytosolic gal-3 may impair the phagocytic capacity of already infected cells by reducing actin cytoskeletal rearrangement (Sano, H., Hsu, D.K., et al. 2003). There are several reports showing the ability of galectins to bind to pathogens, such as viruses (Levroney, E.L., Aguilar, H.C., et al. 2005, Ouellet, M., Mercier, S., et al. 2005), bacteria (Barboni, E., Coade, S., et al. 2005, Fowler, M., Thomas, R.J., et al. 2006), (Mey, A., Leffler, H., et al. 1996), *Candida* sp., (Kohatsu, L.,

Hsu, D.K., et al. 2006), and the helminth *Schistosoma mansoni* (van den Berg, T.K., Honing, H., et al. 2004). In addition, gal-3 and gal-9 bind *Leishmania major* (Pelletier, I., Hashidate, T., et al. 2003, Pelletier, I. and Sato, S. 2002, van den Berg, T.K., Honing, H., et al. 2004). Regarding *T. cruzi*, only gal-3 has been described to interact with the parasite (Kleshchenko, Y.Y., Moody, T.N., et al. 2004, Moody, T.N., Ochieng, J., et al. 2000) to promote adhesion to coronary artery smooth muscle cells and to extracellular matrix via a laminin bridge. Our data provide evidence that gal-3 binds *T. cruzi* amastigote surface, and for the first time we provide evidence that also other galectin members like gal-1, 4, 7, 8 can bind the parasite, preferentially amastigotes and cell derived trypomastigotes of all genetic lineages of *T. cruzi*. Of note, galectin binding may render more productive infections for the parasite protozoan. The relevance of *T. cruzi*-galectin interaction might vary depending on the individual galectin and on the cell type or matrix component that the parasite interacts with. If that is the case; our data suggest that *T. cruzi* could use different combinations of galectins to adhere and to infect cells in different tissues, perhaps reminiscent of the differential tropism exhibited by different lineages.

Gal-7, located mainly on skin and stratified epithelia (Magnaldo, T., Bernerd, F., et al. 1995, Magnaldo, T., Fowlis, D., et al. 1998) is the only galectin that showed significant binding to the epimastigotes form. Epimastigotes are present on the vector and despite some reports showing infectivity (Burger, E., Lay, W.H., et al. 1982), they are generally considered to be non-infective. The significance of this might be related to the presence of epimastigotes or metacyclic trypomastigotes excreted in the faeces (Schaub, G. and Losch, P. 1988). That opens the possibility that gal-7, located at the point of parasite entry, such as the skin, could have evolved to interact with parasite forms found there at the moment of infection, before new infective forms arise in the host.

Using a classical approach of affinity chromatography allowed us to partially identify, by peptide mass fingerprinting, a very limited and restricted group of membrane proteins from cell-derived trypomastigotes as ligands. Two proteins were found to be recognized

by all the human galectins tested, the putative protease GP63, GP90. The GP82, a putative mucin (TcMUCII) and a putative transialidase were also common ligand partners for the human galectins tested in this study. Using an alternative approach like western blot using soluble streptavidin-labeled galectins, in which the multivalency of galectins is preserved, we could observe many more unidentified ligands. A band around 70-80 KDa was the main *T. cruzi* trypomastigote ligand of all the galectins tested. We could identify just one potential ligand of gal-3, gal-7 and gal-8 as the mucin AgC10 (Alcaide, P. and Fresno, M. 2004a, Alcaide, P. and Fresno, M. 2004b, Kierszenbaum, F., Fresno, M., et al. 2002). Moody et al showed a 45KDa parasite mucin that was detected as a gal-3 ligand (Moody, T.N., Ochieng, J., et al. 2000) that could be AgC10. Gal-3 could be implicated in the immunosuppressor activities attributed to the mucin, as is known that gal-3 modulates T cell responses by control of TCR clustering at the immune synapse (Demetriou, M., Granovsky, M., et al. 2001). Other galectins might be concerned as it could bind to common receptors (Patnaik, S.K., Potvin, B., et al. 2006), although the biological functions derived from different transduction signals must not be necessarily the same.

As galectins are multivalent proteins, they can cross-link receptors mediating cell-cell adhesion and/or cell-extracellular matrix. Therefore, experiments were conducted to evaluate the ability of galectins to promote parasite adhesion to host cells. The galectin-induced adhesion was both concentration- and CRD-dependent. When gal-8 null mutant was used, adhesion was abrogated, suggesting that an active CRD is required to favour parasite adhesion to host cells. Nevertheless, the gal-8 mutant that has a non-functional N-terminal domain, gal-8R233, is still able to promote parasite adhesion to host cells, although in a lesser extent than the wild type. Gal-8R233 is supposed not to cross-link glycosylated receptors, as only one terminal domain of the protein keeps carbohydrate recognition domain. It could be argued that the mutated CRD interacts with some host molecules in a sugar independent way. However, that is not occurring in the parasite binding because lactose inhibits wild type gal-8 binding to

the parasite. Another explanation, although galectin-8 is a tandem repeat, is that the protein can form homodimers through the N-terminal CRD, as it has been published before (Stowell, S.R., Arthur, C.M., et al. 2008). In that way gal-8 could still bind with relative high affinity to cognate ligands.

A way in which the galectin binding to the parasites could be modified is by altering the galectin ligands exposure, for example by β -galactosidases or the sialyltransferase ST6 (Zhuo, Y. and Bellis, S.L. 2011) acting as negative regulators. It could be argued that the transialidase (TS) from *T. cruzi*, considered a virulence factor, could act as such modulator, but that is not the case as the TS does not transfer sialic acids linked α 2-6 (Vandekerckhove, F., Schenkman, S., et al. 1992) and hence could not modify the galectin binding to host self-ligands, however there are no reports of *T. cruzi* β -galactosidase as virulence factor.

By evaluating whether different reference strains with clearly distinct biological behaviour exhibit differential binding to host immune proteins like galectins, support to the notion that specific traits in the different genetic lineage or DTUs of *T. cruzi* could be associated to differential pathology is provided. If there is a differential galectin binding profile for each genetic lineage, that could mean that different immune responses networks would be triggered at different tissues and eventually be correlated to the differential course of the Chagas' disease pathology. This analysis allowed to build a tree with six groups clearly defined, that closely resembles the one built solely on genetic data.

A parallel analysis taking the similarity matrix build on amastigote-galectin binding profile data arranged the different lineages in five clusters containing each one a single DTU and a mixed cluster containing DTUs IV and V together.

Our findings are compatible with the idea that DTUs II (arranged in the tree far apart from the rest) and I are ancient parental lineages and that DTUs IV and V are recent ones derived from at least one recombination event (one cluster together or very

close). This is to our best knowledge the first report of clustering the DTUs based on biological properties.

A great limitation of UPGMA is that it assumes the same evolutionary speed on all lineages, i.e. the rate of mutations is constant over time for all lineages in the tree, and so we must be very cautious implying that the rate of changes in glycan modifications on each lineage is constant and that the distances reflect true evolutionary distance. It is clear that further studies including more strains and isolates is necessary before any conclusions can be raised.

The results also reflect changes in the composition and quantity (ratio of enzymes involved in synthesis/modification of glycans) of “glycogenes” in the lineages genomes. It must be considered here that glycoconjugates are not direct products of the genome, but the result of a series of variable sequences of “glycogenes” actions, and subtle changes on them may result in a great diversity of structures, and for sure such variations may have profound implications in virulence, antigenicity and immune response deriving in variable pathogenesis (Varki, A. 2011). It is known that *T. cruzi* lineages (Araujo, C.A., Mello, C.B., et al. 2002), or different strains showing dissimilar infectivity/virulence (Piazza, R.M., Borges, M.M., et al. 1996) can be distinguished *in vitro* by their different affinity towards PNA, suggesting that different lineages exhibit different glycans on their surface. This has been recently confirmed by (Soares, R.P., Torrecilhas, A.C., et al. 2012) showing differential expression of α -galactosyl residues in *T. cruzi* GPI-mucins, and by our group showing differential glycan profile by different strains of *T. cruzi* (Bonay and Staudacher, manuscript in preparation).

The composition of lineages in a natural infecting population may play a role in determining the outcome of the infection and may reflect the differential interaction with host proteins regulating the immune response. Providing evidence of discriminant reactivity of a family of immune relevant proteins against different lineages imposes new views on the causes and progression of the wide spectra of disorders associated to the disease. In addition, it reinforces the notion that differential outcomes of *T. cruzi*

infection could be influenced by the complexity of the infecting *T. cruzi* population that interferes with host factors related to regulation of acute inflammatory response essential for protection against infection, but may also contribute to pathology. This represents the first step to extend this analysis to another relevant protein in order to increase the view on how the innate immune system perceives the different parasites/strains and thus provides a clue to elaborate complex networks of interactions and deciphers the fine-tuning events occurring with complex pathogens.

Acknowledgments

This work was supported by grants from the Fondo de Investigaciones Sanitarias-Ministerio de Sanidad (FIS-PI11/00033) to PB and (FIS-PI11/0095) to MS, and grant ChagasEpiNet (European VII framework Program) to MF. The financial support Network RICET from the FIS, Ministerio de Sanidad and Fundacion Ramon Areces is acknowledged.

References

- Alcaide P, Fresno M. 2004a. AgC10, a mucin from *Trypanosoma cruzi*, destabilizes TNF and cyclooxygenase-2 mRNA by inhibiting mitogen-activated protein kinase p38. *Eur J Immunol*, 34:1695-1704.
- Alcaide P, Fresno M. 2004b. The *Trypanosoma cruzi* membrane mucin AgC10 inhibits T cell activation and IL-2 transcription through L-selectin. *Int Immunol*, 16:1365-1375.
- Alcaide P, Lim YC, Luscinskas FW, Fresno M. 2010. Mucin AgC10 from *Trypanosoma cruzi* Interferes with L-selectin-mediated monocyte adhesion. *Infect Immun*, 78:1260-1268.
- Alcina A, Fresno M. 1988. A tubulin-related 55 kilodalton surface antigen recognized by different *Trypanosoma cruzi* stage-specific monoclonal antibodies from infected mice. *Molecular Biochemistry Parasitology*, 29:181-190.
- Almeida IC, Camargo MM, Procopio DO, Silva LS, Mehler A, Travassos LR, Gazzinelli RT, Ferguson MA. 2000. Highly purified glycosylphosphatidylinositols from *Trypanosoma cruzi* are potent proinflammatory agents. *Embo J*, 19:1476-1485.
- Almeida IC, Gazzinelli R, Ferguson MA, Travassos LR. 1999. *Trypanosoma cruzi* mucins: potential functions of a complex structure. *Mem Inst Oswaldo Cruz*, 94 Suppl 1:173-176.
- Amit I, Regev A, Hacohen N. 2011. Strategies to discover regulatory circuits of the mammalian immune system. *Nat Rev Immunol*.
- Andersen H, Jensen ON, Moiseeva EP, Eriksen EF. 2003. A proteome study of secreted prostatic factors affecting osteoblastic activity: galectin-1 is involved in differentiation of human bone marrow stromal cells. *J Bone Miner Res*, 18:195-203.
- Aquilino C, Gonzalez Rubio ML, Seco EM, Escudero L, Corvo L, Soto M, Fresno M, Malpartida F, Bonay P. 2012. Differential trypanocidal activity of novel macrolide antibiotics; correlation to genetic lineage. *PLoS One*, 7:e40901.
- Araujo CA, Mello CB, Jansen AM. 2002. *Trypanosoma cruzi* I and *Trypanosoma cruzi* II: recognition of sugar structures by *Arachis hypogaea* (peanut agglutinin) lectin. *J Parasitol*, 88:582-586.
- Barboni E, Coade S, Fiori A. 2005. The binding of mycolic acids to galectin-3: A novel interaction between a host soluble lectin and trafficking mycobacterial lipids? *FEBS Lett*.
- Beatty WL, Rhoades ER, Hsu DK, Liu FT, Russell DG. 2002. Association of a macrophage galactoside-binding protein with Mycobacterium-containing phagosomes. *Cell Microbiol*, 4:167-176.
- Biolo A, Ribeiro AL, Clausell N. 2010. Chagas cardiomyopathy--where do we stand after a hundred years? *Prog Cardiovasc Dis*, 52:300-316.
- Boonstra A, Rajsbaum R, Holman M, Marques R, Asselin-Paturel C, Pereira JP, Bates EE, Akira S, Vieira P, Liu YJ, et al. 2006. Macrophages and myeloid dendritic cells, but not plasmacytoid dendritic cells, produce IL-10 in response to MyD88- and TRIF-dependent TLR signals, and TLR-independent signals. *J Immunol*, 177:7551-7558.
- Bourguignon SC, de Souza W, Souto-Padron T. 1998. Localization of lectin-binding sites on the surface of *Trypanosoma cruzi* grown in chemically defined conditions. *Histochem Cell Biol*, 110:527-534.
- Brener Z. 1973. Biology of *Trypanosoma cruzi*. *Annu. Rev. Microbiol.*, 27:347-382.
- Burger E, Lay WH, Hypolito LV, Fernandes JF. 1982. *Trypanosoma cruzi*: the fate of bloodstream trypomastigote, amastigote, metacyclic trypomastigote and epimastigote forms in the peritoneal macrophages of immune and non-immune mice in vivo. *Acta Trop. Basel.*, 39:111-122.

- Buscaglia CA, Campo VA, Frasch AC, Di Noia JM. 2006. Trypanosoma cruzi surface mucins: host-dependent coat diversity. *Nat Rev Microbiol*, 4:229-236.
- Claycomb WC, Lanson NA, Jr., Stallworth BS, Egeland DB, Delcarpio JB, Bahinski A, Izzo NJ, Jr. 1998. HL-1 cells: a cardiac muscle cell line that contracts and retains phenotypic characteristics of the adult cardiomyocyte. *Proc Natl Acad Sci U S A*, 95:2979-2984.
- Colli W, Alves MJ. 1999. Relevant glycoconjugates on the surface of Trypanosoma cruzi. *Mem Inst Oswaldo Cruz*, 94 Suppl 1:37-49.
- Coura JR, Borges-Pereira J. 2010. Chagas disease: 100 years after its discovery. A systemic review. *Acta Trop*, 115:5-13.
- Chevrier N, Mertins P, Artyomov MN, Shalek AK, Iannacone M, Ciaccio MF, Gat-Viks I, Tonti E, Degrace MM, Clauser KR, *et al.* 2011. Systematic Discovery of TLR Signaling Components Delineates Viral-Sensing Circuits. *Cell*, 147:853-867.
- Chuenkova MV, Pereiraperrin M. 2011. Neurodegeneration and neuroregeneration in Chagas disease. *Adv Parasitol*, 76:195-233.
- Dam TK, Brewer CF. 2010. Lectins as pattern recognition molecules: the effects of epitope density in innate immunity. *Glycobiology*, 20:270-279.
- Dam TK, Brewer FC. 2010. Maintenance of cell surface glycan density by lectin-glycan interactions: a homeostatic and innate immune regulatory mechanism. *Glycobiology*, 20:1061-1064.
- de-Souza W. 1984. Cell biology of Trypanosoma cruzi. *Int. Rev. Cytol.*, 86:197-283.
- de Lederkremer RM, Agusti R. 2009. Glycobiology of Trypanosoma cruzi. *Adv Carbohydr Chem Biochem*, 62:311-366.
- de Lederkremer RM, Colli W. 1995. Galactofuranose-containing glycoconjugates in trypanosomatids. *Glycobiology*, 5:547-552.
- Demetriou M, Granovsky M, Quaggin S, Dennis JW. 2001. Negative regulation of T-cell activation and autoimmunity by Mgat5 N-glycosylation. *Nature*, 409:733-739.
- Ferguson MA. 1997. The surface glycoconjugates of trypanosomatid parasites. *Philos Trans R Soc Lond B Biol Sci*, 352:1295-1302.
- Fowler M, Thomas RJ, Atherton J, Roberts IS, High NJ. 2006. Galectin-3 binds to Helicobacter pylori O-antigen: it is upregulated and rapidly secreted by gastric epithelial cells in response to H. pylori adhesion. *Cell Microbiol*, 8:44-54.
- Gamarro F, Osuna A, Castanys S, Perez-Lopez MI, Ruiz-Perez LM. 1985. Isolation and purification of amastigotes of Trypanosoma cruzi from cultured vero cells. *Z Parasitenkd*, 71:15-17.
- Garcia-Vallve S, Palau J, Romeu A. 1999. Horizontal gene transfer in glycosyl hydrolases inferred from codon usage in Escherichia coli and Bacillus subtilis. *Mol Biol Evol*, 16:1125-1134.
- Giordanengo L, Gea S, Barbieri G, Rabinovich GA. 2001. Anti-galectin-1 autoantibodies in human Trypanosoma cruzi infection: differential expression of this beta-galactoside-binding protein in cardiac Chagas' disease. *Clin Exp Immunol*, 124:266-273.
- Hemmige V, Tanowitz H, Sethi A. 2012. Trypanosoma cruzi infection: a review with emphasis on cutaneous manifestations. *Int J Dermatol*, 51:501-508.
- Kahn S, Wleklinski M, Aruffo A, Farr A, Coder D, Kahn M. 1995. Trypanosoma cruzi amastigote adhesion to macrophages is facilitated by the mannose receptor. *J. Exp. Med.*, 182:1243-1258.
- Kierszenbaum F, Fresno M, Szein MB. 2002. The Trypanosoma cruzi membrane glycoprotein AGC10 inhibits human lymphocyte activation by a mechanism preceding

translation of both, interleukin-2 and its high-affinity receptor subunits. *Mol Biochem Parasitol*, 125:91-101.

Kleshchenko YY, Moody TN, Furtak VA, Ochieng J, Lima MF, Villalta F. 2004. Human galectin-3 promotes *Trypanosoma cruzi* adhesion to human coronary artery smooth muscle cells. *Infect Immun*, 72:6717-6721.

Kohatsu L, Hsu DK, Jegalian AG, Liu FT, Baum LG. 2006. Galectin-3 Induces Death of *Candida* Species Expressing Specific beta-1,2-Linked Mannans. *J Immunol*, 177:4718-4726.

Kopitz J, von Reitzenstein C, Andre S, Kaltner H, Uhl J, Ehemann V, Cantz M, Gabius HJ. 2001. Negative regulation of neuroblastoma cell growth by carbohydrate-dependent surface binding of galectin-1 and functional divergence from galectin-3. *J Biol Chem*, 276:35917-35923.

Levroney EL, Aguilar HC, Fulcher JA, Kohatsu L, Pace KE, Pang M, Gurney KB, Baum LG, Lee B. 2005. Novel innate immune functions for galectin-1: galectin-1 inhibits cell fusion by Nipah virus envelope glycoproteins and augments dendritic cell secretion of proinflammatory cytokines. *J Immunol*, 175:413-420.

Macedo AM, Machado CR, Oliveira RP, Pena SD. 2004. *Trypanosoma cruzi*: genetic structure of populations and relevance of genetic variability to the pathogenesis of chagas disease. *Mem Inst Oswaldo Cruz*, 99:1-12.

Machado FC, Cruz L, da Silva AA, Cruz MC, Mortara RA, Roque-Barreira MC, da Silva CV. 2014. Recruitment of galectin-3 during cell invasion and intracellular trafficking of *Trypanosoma cruzi* extracellular amastigotes. *Glycobiology*, 24:179-184.

Magnaldo T, Bernerd F, Darmon M. 1995. Galectin-7, a human 14-kDa S-lectin, specifically expressed in keratinocytes and sensitive to retinoic acid. *Dev Biol*, 168:259-271.

Magnaldo T, Fowles D, Darmon M. 1998. Galectin-7, a marker of all types of stratified epithelia. *Differentiation*, 63:159-168.

Marques A, Nakayasu E, Almeida I. 2011. Purification of extracellular and intracellular amastigotes of *Trypanosoma cruzi* from mammalian host-infected cells. *Protocol Exchange*, doi:10.1038/protex.2011.265.

Mey A, Leffler H, Hmama Z, Normier G, Revillard JP. 1996. The animal lectin galectin-3 interacts with bacterial lipopolysaccharides via two independent sites. *J Immunol*, 156:1572-1577.

Moody TN, Ochieng J, Villalta F. 2000. Novel mechanism that *Trypanosoma cruzi* uses to adhere to the extracellular matrix mediated by human galectin-3. *FEBS Lett*, 470:305-308.

Nio-Kobayashi J, Takahashi-Iwanaga H, Iwanaga T. 2009. Immunohistochemical localization of six galectin subtypes in the mouse digestive tract. *J Histochem Cytochem*, 57:41-50.

Nishi N, Itoh A, Shoji H, Miyanaka H, Nakamura T. 2006. Galectin-8 and galectin-9 are novel substrates for thrombin. *Glycobiology*, 16:15C-20C.

Nishi N, Shoji H, Seki M, Itoh A, Miyanaka H, Yuube K, Hirashima M, Nakamura T. 2003. Galectin-8 modulates neutrophil function via interaction with integrin alphaM. *Glycobiology*, 13:755-763.

Nogueira NF, Gonzalez MS, Gomes JE, de Souza W, Garcia ES, Azambuja P, Nohara LL, Almeida IC, Zingales B, Colli W. 2007. *Trypanosoma cruzi*: involvement of glycoinositolphospholipids in the attachment to the luminal midgut surface of *Rhodnius prolixus*. *Exp Parasitol*, 116:120-128.

Ouellet M, Mercier S, Pelletier I, Bounou S, Roy J, Hirabayashi J, Sato S, Tremblay MJ. 2005. Galectin-1 acts as a soluble host factor that promotes HIV-1 infectivity through stabilization of virus attachment to host cells. *J Immunol*, 174:4120-4126.

Patnaik SK, Potvin B, Carlsson S, Sturm D, Leffler H, Stanley P. 2006. Complex N-glycans are the major ligands for galectin-1, -3, and -8 on Chinese hamster ovary cells. *Glycobiology*, 16:305-317.

Paz I, Sachse M, Dupont N, Mounier J, Cederfur C, Enninga J, Leffler H, Poirier F, Prevost MC, Lafont F, *et al.* 2010. Galectin-3, a marker for vacuole lysis by invasive pathogens. *Cell Microbiol*, 12:530-544.

Pelletier I, Hashidate T, Urashima T, Nishi N, Nakamura T, Futai M, Arata Y, Kasai K, Hirashima M, Hirabayashi J, *et al.* 2003. Specific recognition of Leishmania major poly-beta-galactosyl epitopes by galectin-9: possible implication of galectin-9 in interaction between L. major and host cells. *J Biol Chem*, 278:22223-22230.

Pelletier I, Sato S. 2002. Specific recognition and cleavage of galectin-3 by Leishmania major through species-specific polygalactose epitope. *J Biol Chem*, 277:17663-17670.

Pereira ME, Krettli AU. 1990. The effect of reinoculation with trypomastigotes on the level of protective antibodies in mice chronically infected with T. cruzi. *Braz. J. Med. Biol. Res.*, 23:283-292.

Piazza RM, Borges MM, Kloetzel JK, Stolf AM. 1996. Reactivity of Trypanosoma cruzi strains with peanut agglutinin (PNA) correlates with number of in vitro infected host cells. *Acta Trop*, 61:41-50.

Previato JO, Wait R, Jones C, DosReis GA, Todeschini AR, Heise N, Previato LM. 2004. Glycoinositolphospholipid from Trypanosoma cruzi: structure, biosynthesis and immunobiology. *Adv Parasitol*, 56:1-41.

Procopio DO, Almeida IC, Torrecilhas AC, Cardoso JE, Teyton L, Travassos LR, Bendelac A, Gazzinelli RT. 2002. Glycosylphosphatidylinositol-anchored mucin-like glycoproteins from Trypanosoma cruzi bind to CD1d but do not elicit dominant innate or adaptive immune responses via the CD1d/NKT cell pathway. *J Immunol*, 169:3926-3933.

Py MO. 2011. Neurologic manifestations of Chagas disease. *Current neurology and neuroscience reports*, 11:536-542.

Rabinovich GA, Gruppi A. 2005. Galectins as immunoregulators during infectious processes: from microbial invasion to the resolution of the disease. *Parasite Immunol*, 27:103-114.

Rassi A, Jr., Rassi A, Marin-Neto JA. 2010. Chagas disease. *Lancet*, 375:1388-1402.

Reignault LC, Barrias ES, Soares Medeiros LC, de Souza W, de Carvalho TM. 2014. Structures containing galectin-3 are recruited to the parasitophorous vacuole containing Trypanosoma cruzi in mouse peritoneal macrophages. *Parasitol Res.*

Sano H, Hsu DK, Apgar JR, Yu L, Sharma BB, Kuwabara I, Izui S, Liu FT. 2003. Critical role of galectin-3 in phagocytosis by macrophages. *J Clin Invest*, 112:389-397.

Schaub G, Losch P. 1988. Trypanosoma cruzi: origin of metacyclic trypomastigotes in the urine of the vector Triatoma infestans. *Exp Parasitol*, 65:174-186.

Silva-Monteiro E, Reis Lorenzato L, Kenji Nihei O, Junqueira M, Rabinovich GA, Hsu DK, Liu FT, Savino W, Chammas R, Villa-Verde DM. 2007. Altered expression of galectin-3 induces cortical thymocyte depletion and premature exit of immature thymocytes during Trypanosoma cruzi infection. *Am J Pathol*, 170:546-556.

Soares RP, Torrecilhas AC, Assis RR, Rocha MN, Moura e Castro FA, Freitas GF, Murta SM, Santos SL, Marques AF, Almeida IC, *et al.* 2012. Intraspecies variation in Trypanosoma cruzi GPI-mucins: biological activities and differential expression of alpha-galactosyl residues. *Am J Trop Med Hyg*, 87:87-96.

Stowell SR, Arthur CM, Slanina KA, Horton JR, Smith DF, Cummings RD. 2008. Dimeric Galectin-8 induces phosphatidylserine exposure in leukocytes through polylectosamine recognition by the C-terminal domain. *J Biol Chem*, 283:20547-20559.

Trinchieri G, Sher A. 2007. Cooperation of Toll-like receptor signals in innate immune defence. *Nat Rev Immunol*, 7:179-190.

van den Berg TK, Honing H, Franke N, van Remoortere A, Schiphorst WE, Liu FT, Deelder AM, Cummings RD, Hokke CH, van Die I. 2004. LacdiNAc-glycans constitute a parasite pattern for galectin-3-mediated immune recognition. *J Immunol*, 173:1902-1907.

Vandekerckhove F, Schenkman S, Pontes de Carvalho L, Tomlinson S, Kiso M, Yoshida M, Hasegawa A, Nussenzweig V. 1992. Substrate specificity of the *Trypanosoma cruzi* trans-sialidase. *Glycobiology*, 2:541-548.

Varki A. 2011. Evolutionary forces shaping the Golgi glycosylation machinery: why cell surface glycans are universal to living cells. *Cold Spring Harbor perspectives in biology*, 3.

Vasta GR. 2009. Roles of galectins in infection. *Nat Rev Microbiol*, 7:424-438.

Vasta GR. 2012. Galectins as pattern recognition receptors: structure, function, and evolution. *Adv Exp Med Biol*, 946:21-36.

Vray B, Camby I, Vercruysse V, Mijatovic T, Bovin NV, Ricciardi-Castagnoli P, Kaltner H, Salmon I, Gabius HJ, Kiss R. 2004. Up-regulation of galectin-3 and its ligands by *Trypanosoma cruzi* infection with modulation of adhesion and migration of murine dendritic cells. *Glycobiology*, 14:647-657.

World OH. 2010. Chagas disease (American trypanosomiasis) fact sheet (revised in June 2010). *Wkly Epidemiol Rec*. p. 334-336.

Zhuo Y, Bellis SL. 2011. Emerging role of alpha2,6-sialic acid as a negative regulator of galectin binding and function. *J Biol Chem*, 286:5935-5941.

Zingales B, Andrade SG, Briones MR, Campbell DA, Chiari E, Fernandes O, Guhl F, Lages-Silva E, Macedo AM, Machado CR, *et al.* 2009. A new consensus for *Trypanosoma cruzi* intraspecific nomenclature: second revision meeting recommends TcI to TcVI. *Mem Inst Oswaldo Cruz*, 104:1051-1054.

Zingales B, Miles MA, Campbell DA, Tibayrenc M, Macedo AM, Teixeira MM, Schijman AG, Llewellyn MS, Lages-Silva E, Machado CR, *et al.* 2012. The revised *Trypanosoma cruzi* subspecific nomenclature: rationale, epidemiological relevance and research applications. *Infect Genet Evol*, 12:240-253.

Zuniga E, Gruppi A, Hirabayashi J, Kasai KI, Rabinovich GA. 2001. Regulated expression and effect of galectin-1 on *Trypanosoma cruzi*-infected macrophages: modulation of microbicidal activity and survival. *Infect Immun*, 69:6804-6812.

Zuniga E, Rabinovich GA, Iglesias MM, Gruppi A. 2001. Regulated expression of galectin-1 during B-cell activation and implications for T-cell apoptosis. *J Leukoc Biol*, 70:73-79.

Figure legends.

Figure 1: Purified galectins are shown after SDS-PAGE.

Samples of each purified recombinant galectin (between 1-3 µg) were separated by SDS-PAGE in a 12% gel and silver stained.

Figure 2: Human recombinant Galectin binding to *T. cruzi* (strain Y, DTU II) is specific for different biological stages.

Alexa488-labeled recombinant human galectins were incubated with three parasite life cycle stages at 4°C and galectin binding was quantified by flow cytometry.

A) Alexa-488-galectins were able to bind *T. cruzi*, and the affinity of galectins was higher for the infective forms of the parasites under the same experimental conditions. Parasites incubated with galectins are shown in solid black, unlabeled negative controls in white.

The insets show a representative micrograph of the parasite population employed for each analysis.

B) Mean of fluorescence intensity (MFI) of galectins (5µM) binding to the three life forms. Median ± SD of five independent experiments is shown.

C) MFI of Alexa-488-labeled recombinant human galectins 1, 3, 7 and 8 bound to cell derived trypomastigotes vs galectin concentration. The median ± SD of five different experiments is shown

Figure 3 Amastigotes and cell derived trypomastigotes bind host galectins.

A) Amastigotes or cell derived-trypomastigotes were washed with lactose or sucrose as described in Materials and Methods before being submitted to Flow Cytometry analysis of galectin binding.

The median ± SD of three different experiments is shown.

* indicates significant at $p < 0.05$

B) Wash media from amastigotes recovered by centrifugation and filtration on 0.22 µM was resolved by SDS-PAGE and WB with specific anti-galectin antibodies (for galectin-1 and 3) or streptavidin-HRP for biotinylated galectin-7.

Figure 4: Intracellular amastigotes bind intracellular pool of galectins.

LLC-MK2 cells (Panel A, C and D) or Vero (Panel B, E and F) growing onto glass coverslips were infected as described. After four days p.i., the cells were processed for

immunofluorescence and stained with anti galectin 1 (A and B), galectin 3 (D) and galectin 7 (E) or just secondary antibody (C and F).

Figure 5: Galectin binding to trypomastigotes is mediated by the CRD.

A) Negative controls are in solid grey, thin black line refers to parasites after incubation with FITC-galectins, 2 μ M, for 15 minutes at 4°C. Parasite-associated fluorescence was quantified by flow cytometry. In the case of galectin-7, the thicker black line (-) corresponds to a galectin concentration of 20 μ M, and the thin line (-) to 2 μ M.

B) Metacyclic trypomastigotes were incubated with FITC labeled galectin-8, and with the FITC labelled mutants R69, R233 and R69R233 for 15 minutes at 16°C. The mean of fluoresce intensity was measured by flow cytometry. All the mutants showed a reduced binding capacity to *T. cruzi*.

C) Flow cytometry analysis of truncated galectin-3 binding to trypomastigotes of *T. cruzi* strain Y. Negative control (no gal-3, white), full length galectin-3 (grey trace), truncated C-terminal CRD of galectin-3 (black trace).

Figure 6: Recombinant human galectins promote parasite adhesion to host cells.

A) Cell-derived trypomastigotes (strain Y) were labeled with CFSE, and incubated with non-labeled cells. Parasites and cells were resolved by flow cytometry due to their different size, and the fluorescence intensity associated to the cell gate (THP- 1) was quantified. Almost 100% of the parasites presented high fluorescence intensity, and only 6% of the cells showed fluorescence intensity when incubated with parasites in the absence of rGals.

B) Aliquots of galectin-8 was added to the mixture of cells and parasites for 10 minutes at 16°C, and the rate of positive cells increased to 43.9% of the total. This binding was abolished in the presence of lactose 50 mM, or when galectin-8 R69, R233 and R69R233 were used instead of the wild type galectin. C) Mean fluorescence intensity is shown using the same approach with gal-1,-3,-4,-7 and -8, at 0.2 μ M and 2 μ M, in the presence and absence of lactose. Representative results from two independent experiments performed is shown. D) Cell-derived trypomastigotes (strain Y, DTU II) were incubated with a LLC-MK2, CaCo and HL-1 cells monolayer for 15 minutes at 16°C in the presence or absence of 2 μ M recombinant galectin, after extensive washing, the attached parasites were counted.

Figure 7: Galectin binding promotes productive infections

Cell-derived trypomastigotes (strain Y, DTU II) were incubated with LLC-MK2 cells for 15 minutes at 16°C in the presence or absence of 2 µM recombinant galectin, after extensive washing, the cells were incubated at 37° for up to five days. At indicated times; cells were washed twice with PBS, fixed with Bouin's fixative solution and stained in Giemsa solution. The intracellular amastigotes were quantified by counting randomly at least 300 cells.

Figure 8: Identification of parasite galectin ligands

A) Cell-derived trypomastigote protein extracts were applied to immobilized galectin columns, washed extensively and eluted with 100mM lactose, resolved by SDS-PAGE, transferred to nitrocellulose membranes and blotted with biotin labeled recombinant galectins, and revealed with streptavidin-HRP.

B) Either Gal-7-GST or Gal-8-GST was immobilized to Glutathion-Sepharose® and cell-derived trypomastigote extracts were applied. GST immobilized was used as a control. After extensive washing, the column was eluted with 100mM lactose. Eluted fractions were subjected to western-blot using specific antibodies against *T. cruzi* mucin AgC10. 1: Gal-7-GST column lactose elution, 2: Gal-8-GST column lactose elution, 3: GST column lactose elution, 4: Blank Sepharose lactose elution, 5, 6: washing elutions, 7: purified AgC10.

Figure 9. UPGMA analysis of galectin binding profiles.

A matrix was built with the data shown in Table II and III, presenting the Median Fluorescence Index (MFI) for the binding of each galectin to cell-derived trypomastigotes (A) or amastigotes (B) of each parasite strain in order to construct a dendrogram reflecting relationships between the different *T. cruzi* DTUs represented by the reference strains used in this study.

Table I

Strains of *T. cruzi* used in this work.

Strain	DTU	Origin	Host/Vector
Silvio/X10 c1	I	Belem, Brazil	<i>Homo sapiens</i>
Dm28c	I	Carabobo, Venezuela	<i>Didelphis marsupialis</i>
Esmeraldo c3	II	Bahia, Brazil	<i>Homo sapiens</i>
Y	II	Sao Paulo, Brazil	<i>Homo sapiens</i>
Tu18 c2	II	Tupiza, Bolivia	<i>Triatoma infestans</i>
Cm17	III	Carimaga, Colombia	<i>Dasyprocta fugiliosa</i>
M6241 c6	III	Para, Brazil	<i>Homo sapiens</i>
Can III c11	IV	Para, Brazil	<i>Homo sapiens</i>
10R26	IV	Santa Cruz, Bolivia	<i>Aotus sp.</i>
Bug2148 c11	V	Rio Grande do Sul, Brazil	<i>Triatoma infestans</i>
Sc43 c1	V	Santa Cruz, Bolivia	<i>Triatoma infestans</i>
Tula c2	VI	Tulahuen, Chile	<i>Homo sapiens</i>
VFRA c1	VI	Francia, Chile	<i>Triatoma infestans</i>
CL-Brener	VI	Rio Grande do Sul, Brazil	<i>Triatoma infestans</i>

Table II

Strain	DTU	MFI gal-1	MFI gal-3	MFI gal-4	MFI gal-7	MFI gal-8
Silvio/X10 c1	TcI	15±3	48±5	14±4	48±4	19±4
Dm28c	TcI	17±4	47±7	15±5	51±9	22±5
Esmeraldo c3	TcII	15±3	19±4	16±7	80±6	30±8
Y	TcII	18±4	15±6	19±5	77±8	26±6
Tu18 c2	TcII	17±5	18±4	21±6	75±8	28±9
Cm17	TcIII	19±3	38±5	20±5	55±7	39±7
M6241 c6	TcIII	22±5	39±7	24±6	60±10	41±6
Can III	TcIV	28±7	38±5	19±7	65±8	46±7
10R26	TcIV	35±7	37±6	18±8	57±10	31±8
Bug2148 c11	TcV	18±5	40±5	16±7	68±6	31±3
Sc43 c1	TcV	19±5	42±3	19±4	78±7	32±2
Tula c2	TcVI	20±5	26±6	21±5	57±5	21±3
VFRA c1	TcVI	21±4	28±2	22±8	49±4	20±3
CL-Brener	TcVI	19±3	27±4	25±4	55±4	24±3

Median fluorescence Intensity (MFI) for each galectin-FITC against cell derived trypomastigotes from the indicated strains. Each flow cytometry analysis was carried out three times and the median \pm SD is shown.

Table III

Strain	DTU	MFI gal-1	MFI gal-3	MFI gal-4	MFI gal-7	MFI gal-8
Silvio/X10 c1	TcI	19±7	25±4	91±10	78±8	47±8
Dm28c	TcI	27±5	27±6	87±8	71±7	41±9
Esmeraldo c3	TcII	87±5	29±8	125±10	79±3	30±8
Y	TcII	78±8	31±5	94±8	58±9	21±4
Tu18 c2	TcII	97±7	35±9	130±12	75±8	28±9
Cm17	TcIII	45±6	88±43	150±11	98±8	61±7
M6241 c6	TcIII	41±8	97±6	112±9	87±11	71±8
Can III	TcIV	39±6	65±7	75±8	99±7	44±8
10R26	TcIV	45±4	59±8	85±7	125±15	43±3
Bug2148 c11	TcV	54±7	71±2	67±4	98±3	41±8
Sc43 c1	TcV	61±3	81±3	57±9	108±11	29±7
Tula c2	TcVI	27±4	52±8	90±4	57±5	31±5
VFRA c1	TcVI	32±8	68±3	81±9	65±3	40±6
CL-Brener	TcVI	39±7	77±9	78±10	70±7	38±7

Median fluorescence Intensity (MFI) for each galectin-FITC against amastigotes from the indicated strains. Each flow cytometry analysis was carried out four times and the median ± SD is shown.

Table IV.

	Protein (MW)	Sequence of identified peptide	Accession number
Galectin1	Surface Protease GP63 putative	R.GRPVVGVINPR.H R.NVGEVTGGEEPASPVTVSVGSDWAPLR.I R.LLVRPLDGPLVVPR.F R.SSVHVVNSR.N R.FREGSVCGK.F	Q4CM87
	GP90	K.AYTVLGPTDGTDNRVGFFYHPTTTTK.L K.QSTIDAHEVK.L K.LTESDSEVMWPVNTR.V K.VFLLVGSLGELK.E R.EPTDSEPTGGITWGEIK.S	AAM47176
	GP82	R.GEIDAQYAVDGK.L K.GNLDVVLSPTTTMMK.G R.KVMLYTQR.G	ABR19835
	Mucin TcMUCII, putative	K.MNVNSEGSNTQEDEEGGRNK.A	EAN93978.1
	Calcium-binding protein	K.VEDPAALFK.E K.LDEFTPR.V	BAA13411.1
	Surface protein-1	K.APSESTPLLGAGLGDNDGTK.F	AAB18265.1
	Trans-sialidase, putative	K.SLLGQIAPQAQGDSK.V K.NFFLYNRPLSADELK.M	EAN98599.1
Galectin3	Surface Protease GP63 putative	R.LLVRPLDGPLVVPR.F K.VDILENVILSEAAK.M	Q4CM87
	GP90	K.AYTVLGPTDGTDNRVGFFYHPTTTTK.G K.LTESDSEVMWPVNTR.V K.TTESGTWEPGKEYQVAL.M R.KVMLYTQR.G R.EPTDSEPTGGITWGEIK.S	AAM47176
	GP82	K.LVVGEVTKPSAGGEP SG.W K.FTGFGSGAIWPVNNR.E	ABR19835
	Trans-sialidase, putative	K.SLLGQIAPQAQGDSK.V	EAN98599.1
Galectin4	Surface Protease GP63	R.LLVRPLDGPLVVPR.F	Q4CM87

	putative	R.SSVHVVNSR.N R.FREGSVCGK.F R.NVGEVTGGEEPASPVTVSVGSDWAPLR.I R.VAVHEM*AHALGFIVTDM*EGQALVK.R K.VDILENVILSEAAK.M	
	GP90	K.GELSSSLLYSDGNLQLLQQR.G R.VGFFYHPTTTTK.G K.SQSFFSDLK.L R.EPTDSEPTGGITWGEIK.S K.EDGENCLLSTGVSPAK.C	AAM47176
Galectin7	Surface Protease GP63 putative	K.VDILENVILSEAAK.M R.LLVRPLDGPLVVPR.F R.FREGSVCGK.F	Q4CM87
	Mucin TcMUCII, putative	K.MNVNSEGSENTQEDEEGGRNK.A	EAN93978.1
Galectin8	Surface Protease GP63 putative	R.FREGSVCGK.F R.LLVRPLDGPLVVPR.F	Q4CM87
	GP90	R.KVMLYTQR.G K.LTESDSEVMWPVNTR.V K.AYTVLGPTDGTDNRVGFFYHPTTTtK.G R.EPTDSEPTGGITWGEIK.S	AAM47176
	GP82	K.NVFLYNPRPLGADEL.R.M K.FTGFGSGAIWPVNNR.E K.GNLDVVLSPTTTMMK.G	ABR19835
	Mucin TcMUCII, putative	K.MNVNSEGSENTQEDEEGGRNK.A	EAN93978.1

Proteins from *T. cruzi* cell-derived tripomastigoes (strain Y) bound to galectins.